HAI-ROBOTICS
Hai Robotics ("Hai") has joined forces in the inauguration of L'Oréal's SMART Fulfillment Center in Suzhou, China. Located inside Suzhou Industrial Park, this fulfillment center signals Hai's ongoing commitment to support its customers on every step of their warehousing journey with technical expertise, quality service and prompt delivery.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240512209916/en/
From left to right: Shengdong Xu, Chief Technology Officer (Hai Robotics); Richie Chen, Founder and Chief Executive Officer (Hai Robotics); Jean-Luc Laurans, Supply Chain Director North Asia (L'Oréal); Jakub Czaplicki, Fulfillment Factory Director North Asia (L'Oréal); Alan Liu, President of Greater China, Japan & Korea (Hai Robotics); Iris Gu, Key Accounts Manager (Hai Robotics) (Photo: Business Wire)
With an area of 46,000 square meters, this fulfillment center houses Hai's essential goods-to-person solution, HaiPick System 1, including 39 HaiPick A42 Multi-Layer Autonomous Case-handling Mobile Robots (ACR), as well as HaiPort and conveyor picking workstations. L'Oréal is now able to handle D2C (direct-to-consumer) orders with elevated flexibility, efficiency and scalability for L'Oréal, without compromising on intelligence and sustainability for its supply chain operations.
"We are delighted to be a part of L'Oréal's warehousing journey by supporting them with our ACR and goods-to-person technology. This marks a key moment in our partnership," Richie Chen, Founder and CEO of Hai Robotics said. "This new fulfillment center will facilitate supply chain transformation by improving operational efficiency, storage density and flexibility in tackling orders, ultimately elevating the experience for our customers who desire speed and convenience. We are proud to support L'Oréal in achieving their broader business objectives, and look forward to what the future has to bring."
Hai Robotics provides smart and superior ecommerce warehouse solutions for companies to address challenges in order fulfillment, error reduction, return processing etc. These solutions also enable companies to adjust operations flexibly to tackle peak season and adapt to rapid workflow changes. With Hai's automation solutions, warehouses experience increased storage density between 80%-400%, as well as enhanced outbound efficiency by 2.5 times.
The L'Oréal Suzhou SMART Fulfillment Center, equipped with superior automation technology and information systems, will be a key hub in the beauty brand's handling of D2C and B2B orders in Mainland China. It will allow L'Oréal to better support its commercial clients consisting of ecommerce platforms, offline retailers, as well as beauty salons. To learn more about our HaiPick systems, please visit https://www.hairobotics.com/products.
For more information on L’Oréal, please visit https://www.loreal.com/en/mediaroom.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240512209916/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom